Gilead Sciences Inc Stock
Price
Target price
€98.44
€98.44
-0.230%
-0.23
-0.230%
€110.16
11:29 / Tradegate
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Gilead Sciences Inc Stock
Gilead Sciences Inc shows a slight decrease today, losing -€0.230 (-0.230%) compared to yesterday.
The stock is an absolute favorite of our community with 32 Buy predictions and no Sell predictions.
With a target price of 110 € there is a slightly positive potential of 11.74% for Gilead Sciences Inc compared to the current price of 98.44 €.
So far the community has only identified positive things for Gilead Sciences Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Gilead Sciences Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gilead Sciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | -0.230% | 1.848% | 12.650% | 64.697% | 9.853% | 69.478% | 44.805% |
| Exact Sciences | 1.020% | -4.954% | 1.850% | 21.127% | -11.438% | 4.276% | -39.868% |
| Regeneron Pharmaceuticals Inc. | 0.300% | 0.069% | -11.259% | -53.393% | -36.029% | -23.740% | -19.031% |
| Incyte Corp. | 0.230% | 2.689% | 11.617% | 7.378% | -10.530% | -16.012% | -29.757% |
Comments
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $132.00 to $125.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Morgan Stanley from $130.00 to $135.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $120.00 to $130.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
News
Gilead Sciences Stock: HIV Drug Prospects Drive Growth
Morgan Stanley's optimistic outlook for Gilead Sciences' HIV prevention medication Lenacapavir has positioned the company for significant market advancement. The drug, anticipated to receive FDA
Gilead Sciences Stock: FDA Fast-Tracks HIV Drug Review
Gilead Sciences experienced a notable uptick in its NASDAQ trading performance, with shares climbing 1.5% to reach $105.60. This movement brings the stock close to its 52-week high of $106.68
Gilead Sciences Stock: Shares Near 52-Week High Amid Growth
Gilead Sciences is experiencing remarkable momentum on the NASDAQ, with its stock currently trading at $105.25, approaching its 52-week peak of $105.37. The biotechnology company has demonstrated